Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Since our founding, we have helped physicians diagnose and treat more than 75,000 patients and have contributed to many of the most pivotal clinical trials in the pharmaceutical and biotech industries.
Interpace Diagnostics is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Our tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.
For pharmaceutical and biotech companies engaged in oncology-focused clinical trials, Interpace Pharma Solutions offers a comprehensive testing portfolio that can help better select candidate populations and reduce adverse drug reactions. We provide seamless and dynamic coupling of comprehensive project life cycle management and full logistical support with the power of tested platforms for biomarker analysis, anatomic pathology, cytogenetics, and highly customized molecular technologies. Interpace Pharma Solutions has deep knowledge and experience in designing, developing, and validating assays with biomarkers of clinical relevance for cancer diagnosis, prognosis, and theranosis.
Through our various business units, Interpace Biosciences works to improve patient care through personalized medicine driven by offering both molecular diagnostic tests supported by rigorous science and laboratory services supporting every phase of drug development. Via our unique combination of molecular diagnostic tests and laboratory services, healthcare providers will be able to avoid unnecessary surgeries and better assess risk of cancer progression in their patients, while pharmaceutical and biotech companies will be able to deliver safer, more effective compounds to market, and help both clinicians and researchers alike to fulfill the promise of personalized medicine.
Our molecular diagnostic tests and central laboratory services leverage the latest technology to deliver accurate results.
Our experienced pathologists and Ph.D.’s provide professional support for both the Diagnostics and Pharma Solutions teams.
Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. Interpace Diagnostics currently has five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.
As a responsive partner and reliable global provider of high-quality services, Interpace Pharma Solutions’ scientist driven solutions offer support for the spectrum of biomarker research to Phase III clinical trials and companion diagnostic development. We are uniquely positioned to deliver meet the needs of both healthcare providers and biopharma companies to empower personalized medicine disease management.
All of Interpace Biosciences’ testing services are performed within our clinical reference laboratories located in Pittsburgh, PA, New Haven, CT, Rutherford, NJ, and Research Triangle Park, NC which have Clinical Laboratory Improvement Amendment (CLIA) certification and have been accredited by the College of American Pathologists (CAP).